
|Videos|May 31, 2017
Dr. Jun Discusses Cyptogenic Hepatocellular Carcinoma
Author(s)Tomi Jun, MD
Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma.
Advertisement
Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma (HCC).
Although viral liver diseases are seen as the predominant risk factor of HCC, Jun says, there is a population of patients with cryptogenic HCC—mostly those with non-alcoholic fatty liver disease.
Although patients with cryptogenic HCC show less cirrhosis than HCC caused by viral diseases such as hepatitis B and C, the rate of long-term survival is worse.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5



































